在Ipilimumab/nivolumab组合治疗后的液类药物反应:一个病例报告
Zonía Robenne Moore1,2, Dalit Zajdman-Faitelson2, Arely Tamariz Campillo2
1University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
SAGE open medical case reports
|December 22, 2023
概括
检查点抑制剂如尼沃卢马布和伊皮利穆马布可以引起与免疫相关的不良事件. 早期识别和治疗类药物反应至关重要,以防止进展到严重的状况.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 检查点抑制剂,包括nivolumab (PD-1抑制剂) 和ipilimumab (CTLA-4抑制剂),越来越多地用于非小细胞肺癌.
- 与免疫相关的不良事件 (irAEs) 随着这些免疫疗法的广泛使用,越来越令人担忧.
研究的目的:
- 报告一个病人的病例,该病患经历了状药物反应,在nivolumab和ipilimumab的联合治疗期间进展到丸状形式.
- 突出早期皮肤病咨询和干预对irAEs的重要性,以防止严重的皮肤表现.
主要方法:
- 病例报告详细介绍了一名为非小细胞肺癌治疗nivolumab和ipilimumab的患者.
- 临床观察患者的皮肤反应,其进展和对治疗的反应.
主要成果:
- 患者出现了状物药物反应,后演变为状物状物药物反应.
- 随着普得尼松治疗和停止检查点抑制剂,获得了临床解决.
结论:
- 检查点抑制剂治疗期间的类药物反应可以发展为严重的形表现,模仿史蒂文斯-约翰逊综合征.
- 皮肤科医生迅速识别和管理对于预防严重的皮肤毒性和改善患者的治疗结果至关重要.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.2K
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
14.7K
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
01:27Allergic Drug Reactions
846
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
846
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
141
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
141
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
167
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
167
01:29Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145